IL33 and Familial prostate cancer: A high number of ILC2s have been detected mainly in IL-33-enriched tumors, such as breast, gastric and prostate cancer [73,74], since IL-33 is the main ILC2s activator and usually promotes tumor growth, metastases and angiogenesis [75].